RecruitingPhase 2NCT05509153

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

Sponsor

Western Sydney Local Health District

Enrollment

160 participants

Start Date

Jun 1, 2024

Study Type

INTERVENTIONAL

Conditions

Huntington Disease

Summary

NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NAC and a drug called Placebo for people with huntington disease. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNAC

1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day

DRUGPlacebo

Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day

Locations(5)

Westmead Hospital

Westmead, New South Wales, Australia

The University of Queensland

Herston, Queensland, Australia

Calvary Health Care Bethlehem

Parkdale, Victoria, Australia

The Royal Melbourne Hospital

Parkville, Victoria, Australia

Perron Institute

Nedlands, Western Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05509153

Related Trials

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

NCT073786448 locations

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT0732670920 locations

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

NCT0666741445 locations

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

NCT068266125 locations

Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease

NCT075138441 location